News

Colonoscopy's Efficacy Confirmed in Average-Risk Adults


 

FROM THE ANNUAL DIGESTIVE DISEASE WEEK

In contrast, for distal cancers the protective benefit of colonoscopy extended beyond 7 years: Screening colonoscopy provided a significant 42% cancer-rate reduction, compared with no screening, more than 7 years out.

The analysis also showed that the statistically significant protective benefit from polypectomy lasted for just 3 years for all cancer locations, with a 52% protection rate compared with no screening. For distal cancers a significant protective effect lasted for 5 years, but for proximal cancers polypectomy did not provide significant protection, even during the first 3 years after the procedure.

An additional multivariate analysis showed cumulative protection from multiple colonoscopies. A single screening colonoscopy cut the rate of incident cancers, both proximal and distal, by a statistically significant 47%, but two colonoscopies cut the risk by 59% and three or more colonoscopies cut the risk by 64%.

Dr. Lochhead said that he had no disclosures.

Pages

Recommended Reading

Liver Cancer Predictors in Chronic Hepatitis B Identified
MDedge Hematology and Oncology
Use of Ultrasound Expands Across Surgical Specialties
MDedge Hematology and Oncology
Maintenance Immunotherapy Extends Survival in Multiple Advanced Cancers
MDedge Hematology and Oncology
Duodenal GIST Responds to Surgery, Imatinib
MDedge Hematology and Oncology
Intensive Follow-Up Reduces Mortality From Hepatocellular Cancer
MDedge Hematology and Oncology
Fatty Acids in Fish May Lower Liver Cancer Risk
MDedge Hematology and Oncology
Neoadjuvant Abiraterone Helps Clear Aggressive, Early Stage Prostate Tumors
MDedge Hematology and Oncology
Docs Need Primer on Long-Term Effects of Chemotherapy
MDedge Hematology and Oncology
Lymphadenectomy Underused in GI Cancer Surgery
MDedge Hematology and Oncology
Community Oncology Podcast - Aflibercept plus FOLFIRI for metastatic colorectal cancer
MDedge Hematology and Oncology